SK284564B6 - Použitie beta-L-nukleozidovej zlúčeniny na výrobu liečivého prípravku na liečenie nádoru - Google Patents

Použitie beta-L-nukleozidovej zlúčeniny na výrobu liečivého prípravku na liečenie nádoru Download PDF

Info

Publication number
SK284564B6
SK284564B6 SK281-97A SK28197A SK284564B6 SK 284564 B6 SK284564 B6 SK 284564B6 SK 28197 A SK28197 A SK 28197A SK 284564 B6 SK284564 B6 SK 284564B6
Authority
SK
Slovakia
Prior art keywords
tumor
compound according
cancer
oddc
medicament
Prior art date
Application number
SK281-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK28197A3 (en
Inventor
Chung K. Chu
Yung-Chi Cheng
Original Assignee
University Of Georgia Research Foundation, Inc.
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by University Of Georgia Research Foundation, Inc., Yale University filed Critical University Of Georgia Research Foundation, Inc.
Publication of SK28197A3 publication Critical patent/SK28197A3/sk
Publication of SK284564B6 publication Critical patent/SK284564B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK281-97A 1994-09-06 1995-09-05 Použitie beta-L-nukleozidovej zlúčeniny na výrobu liečivého prípravku na liečenie nádoru SK284564B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (en) 1994-09-06 1995-09-05 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
SK28197A3 SK28197A3 (en) 1997-09-10
SK284564B6 true SK284564B6 (sk) 2005-06-02

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
SK281-97A SK284564B6 (sk) 1994-09-06 1995-09-05 Použitie beta-L-nukleozidovej zlúčeniny na výrobu liečivého prípravku na liečenie nádoru

Country Status (31)

Country Link
US (3) US6063787A (zh)
EP (2) EP1468687A1 (zh)
JP (1) JP3979662B2 (zh)
KR (1) KR100374477B1 (zh)
CN (3) CN1827108A (zh)
AP (1) AP783A (zh)
AT (1) ATE267015T1 (zh)
AU (1) AU704977B2 (zh)
BG (1) BG63122B1 (zh)
BR (1) BR9508886A (zh)
CA (1) CA2199117C (zh)
CZ (1) CZ297873B6 (zh)
DE (1) DE69533066T2 (zh)
DK (1) DK0781136T3 (zh)
ES (1) ES2219666T3 (zh)
FI (1) FI970918A (zh)
HU (1) HUT77172A (zh)
IL (1) IL115156A (zh)
IS (1) IS2011B (zh)
MY (1) MY121548A (zh)
NO (1) NO313268B1 (zh)
NZ (1) NZ335013A (zh)
OA (1) OA10473A (zh)
PL (2) PL189288B1 (zh)
PT (1) PT781136E (zh)
RO (1) RO118748B1 (zh)
RU (1) RU2168995C2 (zh)
SI (1) SI0781136T1 (zh)
SK (1) SK284564B6 (zh)
WO (1) WO1996007413A1 (zh)
ZA (1) ZA957483B (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
DE69840216D1 (de) 1997-08-08 2008-12-24 Celmed Oncology Usa Inc Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
PT1045897E (pt) 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica
MXPA00008348A (es) 1998-02-25 2005-07-15 Univ Emory 2-fluronucleosidos.
CN1297281C (zh) * 1999-03-29 2007-01-31 希拉生物化学股份有限公司 治疗白血病的方法
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
DE60011637T2 (de) 1999-09-24 2004-11-11 Shire Biochem Inc., Laval Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
MXPA03003278A (es) * 2000-10-13 2005-07-01 Shire Biochem Inc Analogos de dioxolano para suministro intercelular mejorado.
CA2441350A1 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
HUP0400314A3 (en) * 2001-03-23 2006-02-28 Shire Biochem Inc Laval Pharmaceutical combinations for the treatment of cancer
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
AU2002242561A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
AU2002336864B2 (en) * 2001-11-02 2006-08-17 Shire Biochem Inc. Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
ES2319626T3 (es) * 2001-11-19 2009-05-11 Medigene Ag Farmaco para el tratamiento de enfermedades tumorales y de la piel virales.
WO2004001748A1 (en) 2002-06-21 2003-12-31 Lg Electronics Inc. Recording medium having data structure for managing reproduction of video data recorded thereon
KR100631243B1 (ko) 2002-06-21 2006-10-02 엘지전자 주식회사 비디오 데이터의 재생을 관리하기 위한 데이터 구조를갖는 기록 매체
AU2003241203B2 (en) 2002-06-24 2009-08-20 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
CN1565031B (zh) 2002-06-28 2010-09-29 Lg电子株式会社 一种用于管理多个路径数据的记录和再现的方法及装置
CN100479050C (zh) 2002-10-14 2009-04-15 Lg电子有限公司 具有管理多路音频流重现的数据结构的记录介质及记录和重现的方法和装置
CA2469178C (en) 2002-10-15 2009-09-01 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple graphics streams recorded thereon and recording and reproducing methods and apparatuses
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
EP1604356A4 (en) 2003-02-28 2009-12-16 Lg Electronics Inc RECORD MEDIUM WITH A DATA STRUCTURE FOR MANAGING THE RANDOM / SHUFFLE PLAYBACK OF RECORDED VIDEO DATA, AND METHOD AND DEVICES FOR RECORDING AND PLAYING
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
BRPI0415215B8 (pt) 2003-10-09 2021-05-25 Medigene Ag uso de polifenol na preparação de medicamento
EP1890537B1 (en) 2005-06-07 2012-08-08 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
US7951788B2 (en) 2005-12-02 2011-05-31 Yale University Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
CA2662147A1 (en) * 2006-09-01 2008-03-13 University Of Georgia Research Foundation, Inc. L-oddc prodrugs for cancer
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
ES2905478T3 (es) * 2016-12-28 2022-04-08 Transgene Sa Virus oncolíticos y moléculas terapéuticas
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
AU591125B2 (en) * 1985-05-15 1989-11-30 Wellcome Foundation Limited, The Therapeutic nucleosides
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
IN164556B (zh) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
DE3850571T2 (de) * 1987-03-24 1994-10-27 Nycomed Imaging As 2',3'-dideoxyribofuranoxid-derivate.
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5043339A (en) * 1988-12-19 1991-08-27 Burroughs Wellcome Co. Antiviral compounds
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
DE69232649T2 (de) * 1991-03-06 2002-11-28 Emory University, Atlanta Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995018137A1 (en) * 1993-12-30 1995-07-06 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Also Published As

Publication number Publication date
BG101284A (en) 1998-03-31
AU3586295A (en) 1996-03-27
PT781136E (pt) 2004-09-30
JPH10506385A (ja) 1998-06-23
US20050261320A1 (en) 2005-11-24
KR100374477B1 (ko) 2003-06-19
CZ63397A3 (en) 1997-07-16
IL115156A0 (en) 1995-12-31
JP3979662B2 (ja) 2007-09-19
MY121548A (en) 2006-02-28
AU704977B2 (en) 1999-05-13
NO971015D0 (no) 1997-03-05
CN1251680C (zh) 2006-04-19
DE69533066D1 (de) 2004-06-24
SK28197A3 (en) 1997-09-10
FI970918A0 (fi) 1997-03-04
PL189288B1 (pl) 2005-07-29
AP783A (en) 1999-11-17
KR970705393A (ko) 1997-10-09
US6063787A (en) 2000-05-16
PL318971A1 (en) 1997-07-21
RO118748B1 (ro) 2003-10-30
EP0781136A1 (en) 1997-07-02
FI970918A (fi) 1997-05-02
NO971015L (no) 1997-03-05
EP0781136A4 (en) 1999-06-23
WO1996007413A1 (en) 1996-03-14
BG63122B1 (en) 2001-04-30
ZA957483B (en) 1997-06-06
HUT77172A (hu) 1998-03-02
CN1827108A (zh) 2006-09-06
EP1468687A1 (en) 2004-10-20
DK0781136T3 (da) 2004-08-02
CA2199117C (en) 2006-04-11
CN1448142A (zh) 2003-10-15
CN1111409C (zh) 2003-06-18
US20080171758A1 (en) 2008-07-17
PL188359B1 (pl) 2005-01-31
AP9700939A0 (en) 1997-04-30
US7262213B2 (en) 2007-08-28
OA10473A (en) 2002-04-08
BR9508886A (pt) 1997-12-30
NZ335013A (en) 2000-07-28
ATE267015T1 (de) 2004-06-15
CN1160351A (zh) 1997-09-24
CA2199117A1 (en) 1996-03-14
IS4434A (is) 1997-03-04
SI0781136T1 (en) 2004-08-31
RU2168995C2 (ru) 2001-06-20
DE69533066T2 (de) 2005-06-02
US8076347B2 (en) 2011-12-13
ES2219666T3 (es) 2004-12-01
IL115156A (en) 2000-07-16
CZ297873B6 (cs) 2007-04-18
IS2011B (is) 2005-05-13
NO313268B1 (no) 2002-09-09
EP0781136B1 (en) 2004-05-19

Similar Documents

Publication Publication Date Title
EP0781136B1 (en) Compounds and methods for the treatment of cancer
US5817667A (en) Compounds and methods for the treatment of cancer
BG63121B1 (bg) Таксоиди, тяхното получаване и фармацевтични състави, които ги съдържат
AU781323B2 (en) Anti-viral pyrimidine nucleoside analogues
US8399420B2 (en) Azacytidine analogues and uses thereof
JPH10507772A (ja) Ｌ−リボフラノシルヌクレオシド
US6436948B1 (en) Method for the treatment of psoriasis and genital warts
JP5185823B2 (ja) がん治療用ジオキソラン誘導体

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20090905